Could a common drug keep bladder cancer away?

NCT ID NCT04375813

Ongoing Prevention Sponsor: Robert Svatek Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether a low-dose version of the drug rapamycin, called eRapa, can prevent bladder cancer from coming back in people who have already been treated for non-muscle invasive bladder cancer. About 166 participants will take eRapa or a placebo daily for one year. Researchers will track cancer recurrence, quality of life, and physical and mental function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: encapsulated rapamycin (eRapa)
What this could lead to: If it works, this could offer a new way to prevent bladder cancer from coming back, reducing the need for repeated surgeries or treatments.
What could go wrong: This is a mid-stage trial with 166 participants, so results may not apply to everyone. The drug may not improve recurrence rates, and side effects like immune suppression are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MUSCLE INVASIVE BLADDER CANCER

Contacts and locations

Locations

UT Health San Antonio

San Antonio, Texas, 78229, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.